Research Article

Short-Term and Long-Term Effects of an Exercise-Based Patient Education Programme in People with Multiple Sclerosis: A Pilot Study

Christina Lutz,^{1,2,3} Stephanie Kersten,³ and Christian T. Haas³

¹Sports Science Institute, Saarland University, Campus, 66123 Saarbrücken, Germany

²Faculty of Health Science, LUNEX-International University of Health, Exercise and Sports,

50 Avenue du Parc des Sports, 4671 Differdange, Luxembourg

³Faculty of Health & Social Sciences, Institute for Complex Health Research, Hochschule Fresenius,

University of Applied Sciences, Limburger Straße 2, 65510 Idstein, Germany

Correspondence should be addressed to Christina Lutz; christina.lutz@uni-saarland.de

Received 22 April 2017; Revised 7 July 2017; Accepted 16 July 2017; Published 16 August 2017

Academic Editor: Antonio Bertolotto

Copyright © 2017 Christina Lutz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Although people with Multiple Sclerosis (pwMS) benefit from physical exercise, they still show reduced physical activity and exercise behaviour. This study aimed to investigate short- and long-term effects of an exercise-based patient education programme (ePEP) that focuses on empowering pwMS to a sustainable and self-regulated exercise training management. *Methods.* Fourteen pwMS were randomly assigned to immediate experimental group (EG-I: n = 8) and waitlist-control group (EG-W: n = 6) and attended biweekly in a six-week ePEP. All participants were measured for walking ability, quality of life, fatigue, and self-efficacy towards physical exercise before and after the ePEP, after 12 weeks, and one year after baseline. Short-term effects were analysed in a randomised control trial and long-term effects of all ePEP participants (EG-I + EG-W = EG-all) in a quasi-experimental design. *Results.* Only functional gait significantly improved in EG-I compared to EG-W (p = 0.008, r = -0.67). Moderate to large effects were found in EG-all for walking ability. Not significant, however, relevant changes were detected for quality of life and fatigue. Self-efficacy showed no changes. *Conclusion.* The ePEP seems to be a feasible option to empower pwMS to a self-regulated and sustainable exercise training management shown in long-term walking improvements.

1. Introduction

Numerous studies have demonstrated positive effects of physical exercise in walking ability, fatigue, and quality of life (QoL) in people with Multiple Sclerosis (pwMS) [1–6]. However, pwMS still show reduced physical activity and exercise behaviour compared to healthy people [7–9]. Until now, most of the existing exercise programmes for pwMS are fully supervised and contain a strict training protocol [1]. These programmes rarely analyse long-term effects of physical exercise or focus on the patients' sustainable independence in training management beyond the exercise programme.

Multiple Sclerosis (MS) is a very complex disease and characterised by different disease courses, various symptoms, and an unforeseen disease progress [10–13]. Diurnal and

seasonal changes of disease-related symptoms and conditions require daily disease coping and management. Thus, a predefined and strict exercise programme is hard to implement in patients' everyday life. In order to manage disease and exercise training independently and sustainably, pwMS have to be empowered in MS-specific physical exercises and training management. Patient education programmes (PEPs) pursue a common goal to satisfy these claims of empowerment and are well established in several chronic diseases, as well as in MS [14–16]. However, there is a lack of PEPs that focus on exercise training in MS [16, 17]. The few existing programmes, focusing on physical exercise and activity, are mainly Internet-based interventions containing only one or two types of training (cardiorespiratory and/or strength training) with heterogeneous programme goals based on different theoretical concepts [17]. The German research group around Tallner [18] evaluated an Internetbased physical activity promotion programme (MS-Intact) that provides a three-month individualised exercise training programme focusing mainly on endurance and strength training as well as general physical activity promotion based on Social Cognitive Theory (SCT). Results of this randomised control trial (RCT) showed that the Internet intervention had positive effects on muscle strength, lung function, and physical activity; however there were no effects on QoL, fatigue, or aerobic capacity. The research group around Motl [19] and Dlugonski [20, 21] evaluated in three studies a threemonth Internet intervention based on SCT with the aim of increasing physical activity in pwMS. The intervention did not focus on specific types of exercise training. Results of these three studies showed an increase of physical activity measured by self-reported questionnaires [19] as well as objective measurements [20, 21] and an increase in exercise and physical activity goal setting. A third research group [22] evaluated a face-to-face intervention for increasing selfregulated exercise behaviour and improving important health outcomes in pwMS. The Transtheoretical Model was used as a guiding framework to promote exercise behavioural change. Exercise training comprised mainly aerobic and strength training and to a lesser extent, balance and stretching exercises. The intervention included supervised and homebased exercise sessions with a decrease in supervised sessions over time. Participants increased self-reported exercise volume and improved fatigue and many QoL domains after three months. The improvements in emotional well-being, social function, and overall QoL were maintained for nine months. Although all named studies could indicate some positive effects on physical activity, exercise behaviour, and physical and psychometric conditions, these programmes did not offer a comprehensive exercise-based patient education programme including essential theoretical and practical knowledge of all exercise training types (endurance, strength, coordination, and stretching) that will enable participants to choose and perform a self-regulated, goal-directed, but also motivating, exercise training.

To our knowledge, the pilot study by Kersten et al. [23] is the first that evaluated a comprehensive exercise-based PEP. This programme was designed as a 12-week face-to-face group intervention aiming at long-term self-regulated exercise training for pwMS. Participants significantly improved in walking distance, gait velocity, TUG, fatigue, and QoL after 12 weeks and maintained these improvements in TUG and gait velocity one year after baseline. Qualitative data indicate improvements in self-confidence and the ability of identifying training strategies and barriers. These positive results show that an exercise-based patient education programme is a feasible option: the programme provides salient knowledge about basic physiological functions and training principles and helps patients to apply this knowledge successfully to the exercise training management [23]. Based on these experiences, a revised exercise-based patient education programme (ePEP) with related contents in a more compact form was developed. The aim of this study is to evaluate the effects of the revised six-week ePEP on self-regulated and long-term

exercise behaviour. In contrast to Kersten and colleagues [23], RCT was used to evaluate the immediate effects of the revised ePEP. We hypothesised that teaching pwMS the theoretical and practical essentials of exercising with MS disease, as well as teaching them training- and self-management skills, will enable them to work out independently and sustainably beyond the education phase measured by changes in walking ability, QoL, fatigue, and self-efficacy. Therefore, three working hypotheses were formulated for the different analytic steps.

Hypothesis 1. A six-week ePEP leads to significant differences in walking ability, QoL, fatigue, and *self-efficacy towards physical exercise* in EG-I compared to EG-W.

Hypothesis 2. A six-week ePEP leads to significant differences in walking ability, QoL, fatigue, and *self-efficacy towards physical exercise* in pwMS immediately (T1/T1') and 12 weeks after the ePEP (T2/T2').

Hypothesis 3. PwMS, who attended a six-week ePEP, show significant differences in walking ability, QoL, fatigue, and *self-efficacy towards physical exercise* one year after baseline measurements (*T*3) compared to baseline (*T*0) due to performing self-regulated physical exercise training beyond the intervention.

2. Material and Methods

2.1. Study Design and Procedure. This long-term pilot study was structured in three parts: (1) RCT analysing the immediate effects of the six-week ePEP with a waitlist-control group; (2) a quasi-experimental design (QED) analysing the short-term effects of all participants who received the ePEP, immediately and 12 weeks after the ePEP; and (3) a oneyear follow-up test analysing the long-term effects of all ePEP participants. Please see Figure 1. With the knowledge of beneficial effects of exercise training on health conditions in pwMS, the control period of the waitlist-control group should not take too long. Therefore, the RCT was only proposed for the six-week ePEP. Merging the data of both exercise groups in the QED allows the analysis of a bigger sample size in awareness of possible drop-outs. The study was approved by the local ethics committee of the Hochschule Fresenius, University of Applied Science (Idstein, Germany). Participants were recruited between May and July 2013 by the German Society of Multiple Sclerosis and the health insurance company IKK Südwest and were manually randomly assigned to immediate ePEP group (EG-I) and waitlist-control group (EG-W) by the study board. After baseline measurements (T0), EG-I started with the six-week ePEP, whereas the participants of EG-W were instructed not to change their daily routines. After six weeks, EG-I and EG-W were tested again (T1 = EG-I/T0' = EG-W). While EG-W received the six-week ePEP, EG-I started a 12-week self-regulated training period. EG-W were tested again after the ePEP (T1') and started the 12-week self-regulated training period afterwards. Both groups were tested after their self-regulated training period (T2/T2') and one year after baseline (T3).




FIGURE 1: Flow chart of the study design. *Note*. EG-I: immediate ePEP group; EG-W: waitlist-control group; T0: baseline measurements; T0': second baseline measurements for EG-W; T1/T1': measurements after six-week ePEP; T2/T2': measurements after 12-week self-regulated training period; T3: measurements one year after baseline.

Participants were offered to contact the project board for support on training management.

2.2. Participants. Thirty-five pwMS were recruited and screened for eligibility criteria by their neurologists and general practitioners. Inclusion criteria were as follows: (a) definite diagnosis of MS; (b) age \geq 18; (c) documentation of the current state of disease (EDSS score, medication, and clinical course); (d) disease-related problems in daily life

(self-reported); (e) ability to stand and walk with or without assistive devices (self-reported); (f) physician approval for beginning a physical activity programme; (g) signed letter of written informed consent. Exclusion criteria were as follows: (h) MS relapse, changing medication, or cortisone therapy one month prior to recruitment and during the study; (i) concurrent neurological, internal, or orthopaedic disorders interfering with standing and walking ability; (j) participation in other active therapies during the study. Prior sport participation or affinity was neither an exclusion nor an inclusion criterion. The inclusion and exclusion criteria were only applied for the period of the six-week ePEP and the 12-week self-regulated training. Exclusion criterion (h) was also held for the one-year follow-up test. During the 30and 36-week self-regulated training period, participants were free to make their own decisions in their disease management (medical treatment, diet, etc.) and the implementation of their exercise training. Eighteen out of the 35 pwMS enrolled in the programme remained and were randomly assigned into immediate ePEP group (EG-I: n = 9) and waitlist-control group (EG-W: n = 9). Due to the study design, there was no possible blinding of the participants and study board. Assistances for measurements were blinded. Participants were given written and oral information about the study in advance.

2.3. Intervention. The ePEP was developed based on study results by Kersten et al. [23] to provide pwMS with the knowledge to work out independently. Participants were taught neurophysiological essentials in MS disease, (neuro-) physiological effects of sports, and physical exercises in general and specific for MS, MS-specific recommendations of exercise training [24], training principles, and the importance of resting periods. In order to guarantee a comprehensive treatment, various types of exercise training (cardiorespiratory, strength, coordination/reflex-based, and flexibility) were offered based on individual performance abilities. A main topic of the exercise training was the theory and praxis of highly reflexed-based movements applied as deviancebased gait training (DGT) [25]. There is evidence for an increased production of neurotrophic factors (NF) produced by moderate exercises [26–30] and highly reflex-based movements such as running [31]. These NFs show a beneficial influence on neural function [32] and on relapse remission [33]. In contrast, immobility and forced nonuse may potentiate the neurodegeneration [34]. With respect to existing indications of reduced production of NFs in pwMS [30, 35-37], these neurophysiological contents have been shown to be key aspects in this ePEP and are the theoretical framework for the DGT. The DGT comprises various walking and running exercises such as short sprints, walking alternatively forward, backward, sideward, jumps, and hops, because these are natural (highly) reflex-based movements and lead to an increased NF production compared to swimming or exercises in standing position [31]. Furthermore, the DGT has the aim to vary several movement patterns based on studies of motor learning [38]. These studies recommend variable and random training practice to gain a better performance outcome in retention tests than with constant and blocked training practice. Psychological determinants for adoption and maintenance of health-related behaviour, such as selfefficacy, problem-solving, and patient-generated goal setting were taught in order to enhance patients' exercise motivation and self-management skills [39-41]. Focusing on the sources of self-efficacy, we explained to pwMS the benefits of exercise training (positive outcome expectations) and offered opportunities to experience the four main sources of self-efficacy such as mastery experience, vicarious experience, symbolic experience, and emotional arousal (feedback). Mastery and vicarious experience were made during the practical exercise training in the ePEP and at home. With guidance and support by the sport scientist, group members, friends, or family members, participants gained symbolic experience. Furthermore, external feedback (from the sport scientist, etc.) and internal feedback from the participant (feelings, signs of the body, etc.) will lead to positive emotional arousal. Group discussions, assignments, and the documentation of the training and symptoms were contained in the ePEP to highlight the four experiences and to support participants in the acquisition of strategies for problem-solving. Besides, we taught pwMS how to set individual goals using the S.M.A.R.T. concept [41]. The main contents of each lesson are shown in Table 1. The ePEP were delivered over six weeks, twice a week for 60 to 90 minutes per session. The theoretical and practical contents were provided in a distribution of 40:60 per lesson with different pedagogical methods to consider physical and mental fatigue and to provide an optimal learning atmosphere. Predefined and self-chosen breaks were undertaken for the physical and mental regeneration. The sessions were supervised by at least one sport scientist and one assistant. Two patient booklets with theoretical background and practical information were provided for the participants to exercise and complete homework beyond the sessions. The participants were encouraged to document their training habits, any symptoms, and daily activities in order to analyse experiences, training progression, or contraindications. After the ePEP, pwMS performed their exercise training with a selfgenerated training schedule autonomously at home for 12 weeks and a further 30 (EG-W) or 36 (EG-I) weeks until one year after baseline.

2.4. Measurements. Walking ability and psychometric outcomes were measured in the EG-I at four test times (T0, T1, T2, and T3). The EG-W had one additional measurement after their control period (T0'). Please see Figure 1.

2.4.1. Walking Ability. Walking endurance was measured using the Six-Minute-Walk-Test (6MWT) as a valid and reliable measurement to assess functional walking capacity in people with pulmonary diseases as well as in pwMS [42-44]. Participants were instructed to walk as far as possible in six minutes, using their regular assistive devices if needed. Walking speed was assessed by Timed-Up-and-Go-Test (TUG), which is a quick, reliable, and valid test to quantify functional mobility [45, 46]. The fastest trial time out of three was used for further analyses. The Functional Gait Assessment (FGA) is a further development of the Dynamic Gait Index and assesses postural stability during various walking tasks. It is evaluated for neurological diseases (e.g., Parkinson Disease, Strokes) and for older adults [47-51]. The FGA includes ten items, where performance of each item is rated from 0 (severe impairments) to 3 (normal gait), with a maximal FGA sum score of 30 points [47, 48].

2.4.2. Quality of Life. The Multiple Sclerosis International Questionnaire of Quality of Life (MusiQol) is a valid and

Lesson	Theoretical contents	Practical contents
(1) Essentials of MS, physical exercises, and sports	(i) Neurophysiological basics of MS(ii) Effects of physical exercises and sport in general and specifically for MS	(i) DGT
(2) MS-specific physical exercises and sports	(i) Reflex-based exercises and activities(ii) Neurotrophic factors and MS	(i) Warm-up: DGT (ii) Main programme: aerobics/dancing
(3) Coordination training	(i) Essentials* of coordination training(ii) Essentials* of DGT	(i) Warm-up: coordinative exercises and gameswith balls(ii) Main programme: DGT (patient-led)
(4) Self-management	(i) Comfort and learning zone(ii) Self-efficacy	(i) Warm-up: game with coordinative exercises(patient-led)(ii) Main programme: balance training
(5) Strength training	(i) Neuromuscular basics(ii) Essentials* of strength training	(i) Warm-up: DGT (patient-led)(ii) Main programme: strength training(iii) Cool down: stretching
(6) Training management	(i) Basics of training process (model of super compensation)(ii) Training principles	(i) Warm-up: DGT(ii) Main programme: strength training with latex resistance bands(iii) Cool down: stretching
(7) Cardiorespiratory training	(i) Essentials* of cardiorespiratory training(ii) Determinants in training control (e.g., heart rate measurement, symptoms)	(i) Warm-up: DGT(ii) Main programme: cardiorespiratory training(continuous or interval training)(iii) Cool down: stretching
(8) Cardiorespiratory and flexibility training	(i) Essentials [*] of flexibility training	(i) Warm-up: game with balls(ii) Main programme: cardiorespiratory training(continuous or interval training)(iii) Cool down: stretching
(9) Motivation and training barriers	(i) Motives, motivation/lack of motivation for physical exercise(ii) Attribution theory(iii) Problem solving skills	(i) Warm-up: DGT (outdoor) (ii) Main programme: strength training (iii)Cool down: stretching
(10) Goal setting	(i) Goal setting: S.M.A.R.T.(ii) Training schedule: principles and instructions(iii) Homework: design individual goals and training schedule	(i) Warm-up: football(ii) Main programme: game with contents of strength and coordinative training
(11) Training schedule and repetition	(i) Discussion of self-designed training schedule; optional consultation	(i) MS Olympics (game consisted of quizzes and exercises)
(12) Final discussion	 (i) Discussion of quiz solutions (MS Olympics) and victory ceremony (ii) Instructions and optional consulting for the self-regulated training period (iii) Final feedback 	(i) DGT (ii) Final game

TABLE 1: Theoretical and practical contents of the ePEP lessons.

Note. * included definition, aims, exercises, training methods, training adaption; DGT: deviance-based gait training.

reliable multidimensional, 31-item questionnaire for assessing disease-specific QoL in pwMS [52, 53]. It has been evaluated for the German language and has been shown to provide validity and reliability [53]. Cronbach's alpha coefficients ranged from 0.68 to 0.92 as reported in the previous study [52]. The global index score is calculated as the mean of the nine individual dimension scores. A higher score indicates a higher QoL [54].

2.4.3. Fatigue. The WEIMuS scale (German: Würzburger Erschöpfungsinventar bei MS) is a two-dimensional questionnaire to detect fatigue (total, mental, and physical) by 17

items and is validated in German pwMS [55]. Reliability analyses in the German evaluation study indicated Cronbach's alpha coefficient of 0.92 [55]. A high sum score indicates increased fatigue.

2.4.4. Self-Efficacy. The SSA scale (German: Selbstwirksamkeit zur sportlichen Aktivität) was used to measure selfefficacy towards physical exercise [56]. The SSA scale consists of 12 items; a high sum score indicates a high degree of conviction to execute physical exercises despite barriers. The SSA scale is a valid and reliable measurement of selfefficacy towards physical exercise with a satisfactory internal

	EG-I $(n = 8)$	EG-W $(n = 6)$	<i>p</i> value
Gender, <i>n</i> (male/female)	1/7	0/6	ns
Age (years), mean (±SD)	52.4 (±10.4)	56.0 (±7.4)	ns
EDSS score, median (IQR)	3.5 (2.25-3.5)	3.5 (2.0-3.5)	ns
Time since diagnosis (years), mean \pm SD	12.5 (±10.0)	17.2 (±7.4)	ns
Type of MS, <i>n</i>			
RRMS/PPMS/SPMS/benign	3/3/1/1	4/1/1/0	ns
Level of education			
Low/middle/high	1/2/5	0/3/3	ns
Medication, <i>n</i>			
Immuno/symptom/none	5/2/1	3/1/2	ns
Employment status, <i>n</i>			
Employed/unemployed	4/4	4/2	ns
Unemployed due to MS	4	1	_

 TABLE 2: Sample characteristics.

Note. Mean (±SD) and median (IQR: interquartile range 25th–75th) are given for baseline *T*0; *p* values were computed by Fisher-Freeman-Halton exact test for discrete variables and Mann–Whitney *U* test for continuous variables (two-tailed; $p \le 0.05$); EG-I: immediate ePEP group; EG-W: waitlist-control group; ns: not significant; EDSS: Expanded Disability Status Scale; immuno: immunotherapy; symptom: symptomatic therapy; low education level: lower secondary school (years 5–9); middle education level: secondary school (years 5–10); high education level: A-level (German university entrance qualification; years 5–13).

consistency of alpha = 0.89 as reported from Fuchs and Schwarzer [56].

2.5. Statistical Analyses. Only participants who attended a minimum of 80% of all ePEP lessons were considered for statistical analyses. Ordinal or skewed data and the small sample size, resulting from per protocol analysis, required the application of exact nonparametric tests for statistical analyses (SPSS Statistics version 21, IBM, Inc., Chicago, IL). Statistical *p* value was set at $p \leq 0.05$. Differences in baseline between EG-I and EG-W were analysed by Fisher-Freeman-Halton exact test for categorical variables and by Mann-Whitney U test for continuous variables. Analysing the immediate effects of the ePEP in the RCT, Mann-Whitney U test (twotailed) was used to test significant differences between groups on change scores for T0 and T1 measures. Analysing the immediate effects of the ePEP and the effects after 12-week self-regulated training period of all ePEP participants in the QED, Friedman test was used to assess statistical difference in EG-all (EG-I + EG-W) over time (T0/T0', T1/T1', andT2/T2'). In case of significance, post hoc tests (Wilcoxon Signed Rank test) with Bonferroni adjustments were applied. Wilcoxon Signed Rank test (two-tailed) was used to analyse the long-term effects of the ePEP one year after baseline measurements (T3) compared to baseline (T0/T0').

Effect sizes were calculated using the formula r = z/square root of N (N = number of total observations), which is recommended for skewed distributed variables [57]. Z-scores were taken from SPSS results of Mann–Whitney U test and Wilcoxon Signed Rank test. Effects for r are classified into small (r = 0.10), moderate (r = 0.30), and large (r = 0.50) effects [58].

3. Results

3.1. Baseline. For the RCT, participants were randomly assigned into EG-I (n = 9) and EG-W (n = 9). Due

to cancellation of four participants prior to the start of the study, only eight participants remained for EG-I and six participants for EG-W with no significant differences in sample characteristics and baseline measurements between the groups. Please see Table 2. EG-I consisted of seven women and one man with a mean age of 52.4 (SD \pm 10.4), a median EDSS score of 3.5 (IQR: 2.25-3.5), and a mean disease duration of 12.5 (SD \pm 10.0) years. EG-W, only women, had a mean age of 56.0 (SD \pm 7.4), a median EDSS score of 3.5 (IQR: 2.0–3.5), and a mean disease duration of 17.5 (SD \pm 7.4). For the evaluation of the QED, outcomes of both groups (EG-I/EG-W) were summarised in EG-all for T0/T0', T1/T1', T2/T2', and T3. Six participants were lost to the one-year follow-up test (holidays: n = 2, illness: n = 2, and no answer: n = 2). The compliance during the six-week ePEP was high with an attendance over 80% for all participants (= not more than two missing lessons). No adverse events were reported during the study.

3.2. Immediate Effects of Intervention after Six-Week ePEP (RCT). Mann–Whitney U test on change scores showed a significant difference and a large effect between the groups for FGA (Z = -2.503, p = 0.008, and r = -0.67) only. No statistical differences were detected for TUG, 6MWT, MusiQol, WEIMuS (total, mental, and physical fatigue), and SSA. Nevertheless, MusiQol (Z = -1.291, r = -0.35), physical fatigue (Z = -0.523, r = -0.14), and TUG (Z = -1.033, r = -0.28) showed small to moderate effect sizes and increased mean values in EG-I compared to EG-W. Please see Table 3.

3.3. Short-Term Effects of Intervention after Six-Week ePEP and after 12-Week Self-Regulated Training Period (QED). Significant changes over time (T0/T0', T1/T1', and T2/T2') were found for EG-all in TUG ($\chi^2 = 10.29$, p = 0.004), 6MWT ($\chi^2 = 10.58$, p = 0.005), and FGA ($\chi^2 = 17.08$, $p \le 0.001$) (Table 4). Post hoc analyses showed significant improvements with moderate to large effect sizes from T0/T0' to T1/T1' for

		EG-I $(n = 8)$			EG-W ($n = 6$)		Difference between groups	etween
Variable	T0	T1	Change from T0-T1	T0	T1	Change from $T0-T1$)	Effort circo
	mean ± SD	mean ± SD	mean (%)	mean ± SD	mean ± SD	mean (%)	Z-score	
	median (IQR)	median (IQR)	median (IQR)	median (IQR)	median (IQR)	median (IQR)		r
	7.8 ± 1.8	7.2 ± 1.6	0.5 (+7.1)	7.8 ± 1.6	7.2 ± 1.2	0.6(+8.1)	1 0.33	000
1 UG (S)	7.8 (6.2–9.4)	7.0 (6.0-8.3)	0.2 (-0.0 - 1.5)	6.9(6.1 - 8.5)	6.7 (5.6–7.7)	0.5(0.3-0.9)	ccn.1-	07.0-
	483.2 ± 89.7	496.1 ± 128.4	-12.9(+2.7)	526.0 ± 117.5	530.5 ± 153.8	-4.5(+0.8)		000
6MW 1 (m)	488.1 (399.1-541.5)	501.0 (396.1-568.3)	-21.5(-38.2-11.6)	477.6 (393.4-620.9)	532.2 (448.2-639.0)	-17.0(-37.4-34.7)	667.0-	-0.08
	19.5 ± 4.0	25.4 ± 3.7	-5.9(+30.1)	20.7 ± 6.6	23.3 ± 6.9	-2.7 (+12.9)	0 ECO*	190
FUA (Scure)	20.5(15.5 - 21.8)	25.5 (23.5–28.8)	-6.0(-8.0-4.0)	25.5(17.8 - 28.5)	28.0(21.8 - 30.0)	-2.5(-4.00.8)	COC.7-	-0.0/
() [68.1 ± 10.6	77.2 ± 11.4	-9.1(+13.4)	70.0 ± 7.8	74.6 ± 11.5	-4.6(+6.5)	1001	10.0
INTUSIQUE (SCOTE)	69.2 (60.6–75.6)	79.5 (66.0-86.2)	-9.8(-15.80.4)	74.9(49.8 - 83.4)	75.1 (62.9–84.4)	-5.6(-9.80.6)	-1.271	cc.u-
TATETA ()	26.0 ± 17.7	22.1 ± 15.5	3.9(+14.9)	21.3 ± 6.1	18.8 ± 9.2	2.5 (+11.7)	0 1 05	0.05
W ELIVIUS (SCOFE)	28.5(6.5 - 40.3)	22.0(7.3 - 34.0)	2.0(-4.0-11.5)	15.5(12.5-29.0)	11.5(9.5 - 19.3)	0.0(-4.8-9.5)	CK1.U-	cn.u-
Manual fatimes (anone)	10.5 ± 10.2	9.5 ± 8.4	1.0(+9.5)	8.8 ± 3.9	7.5 ± 2.3	1.3(+15.1)	266.0	000
Mellial Jaugue (score)	6.0(1.3-22)	9.0(1.0-16.0)	0.0(-1.0-1.8)	7.0 (2.8–10.5)	8.0(5.5 - 9.3)	1.0(-2.5-5.0)	070.0-	60.0-
Dhristical fations (conta)	15.5 ± 10.0	12.6 ± 8.3	2.9(+18.5)	12.5 ± 5.8	11.3 ± 8.4	1.2 (+9.3)	0 573	V L O
ruysical taugue (score)	19.0(4.0-22.8)	12.5(5.8-20.0)	1.0(-3.0-10.3)	6.5(4.5 - 9.5)	7.5(4.8-22.0)	-1.5(-3.5-7.5)	C7C.U-	-0.14
	4.7 ± 0.7	4.2 ± 0.8	0.5(-10.8)	4.4 ± 1.3	4.6 ± 1.8	-0.2(+3.4)	7770	510
(and (score)	4.9(4.4-5.3)	4.45(3.8-4.7)	0.2 (-0.1 - 1.5)	4.6(2.9-6.2)	4.5(3.4-6.4)	0.2 (-0.7 - 0.4)	-0.040	/1.0-
<i>Note.</i> Positive percentage v $r = z/square root of N_i * d$ waitlist-control group; $T0^{-1}$ Test; FGA: Functional Gait λ	ralues indicate improver enotes statistically signi baseline measurements; Assessment; MusiQol: M	ments and negative percel ificant difference between (; 71: measurements after si Aultiple Sclerosis Internati	<i>Note.</i> Positive percentage values indicate improvements and negative percentage values indicate declines; Z-scores were taken from results of Mann–Whitney U test; effect size r was computed using formula $r = z/s$ quare root of N_i : \ast denotes statistically significant difference between changes of scores of the groups ($p \leq 0.05$) for exact p value of Mann–Whitney U test (two-tailed). EG-1: immediate ePEP group; EG-W: waitlist-control group; $T0$: baseline measurements; $T1$: measurements after siz-week ePEP; SD: standard deviation; IQR: interquartile range (25th–75th); TUG: Timed-Up-and-Go-Test; 6MWT: Six-Minute-Walk-Test; FGA: Functional Gait Assessment; MusiQoI: Multiple Sclerosis International Questionnaire of Quality of Life; WEIMuS: German MS-specific fatigue questionnaire—lower values indicate fatigue improvement;	nes; Z-scores were taken ups ($p \le 0.05$) for exact $_{l}$ 1 deviation; IQR: interqui ity of Life; WEIMUS: Gerr	from results of Mann–W <i>p</i> value of Mann–Whitney artile range (25th–75th); T man MS-specific fatigue qu	hitney U test; effect size r U test (two-tailed). EG-I: ii UG: Timed-Up-and-Go-Te aestionnaire—lower values	was computed nmediate ePEP sst; 6MWT: Six- indicate fatigue	asing formula group; EG-W: Minute-Walk- improvement;
SSA: scale for self-efficacy towards physical exercise.	owards physical exercis	je.						

Multiple Sclerosis International

TABLE 3: RCT outcomes in walking ability, QoL, fatigue, and self-efficacy for immediate ePEP group and waitlist-control group at baseline (T0), after six-week ePEP (T1).

5								
			EG-all $(n = 14)$	~			Doet hoe	Doet have
	T0/T0'	T1/T1'	Douccutace	T2/T2'	Descentered	Friedman	T0_T1	$T0_{-}T2$
Variable	(n = 14)	(n = 14)	rencentage	(n = 14)	rei centage	T0-T2	7-500	71-01 Z-score
	mean ± SD	mean ± SD	TO TI	mean ± SD		X^2 -score	L-score (affart eiza r)	(affact cize r)
	median (IQR)	median (IQR)	11-01	median (IQR)	71-01			
	7.5 ± 1.5	7.0 ± 1.4	C [6.7 ± 1.1	- 10 1	10.00*	-2.45^{*}	-2.76^{*}
1 UG (S)	7.2 (6.1–8.8)	7.0 (5.7–7.7)	+/.2	6.8(5.8-7.6)	+10.1	10.29	(-0.46)	(0.52)
CAMATT ()	494.3 ± 113.3	516.5 ± 121.1	U 7 -	539.0 ± 98.4	C 0 1	10 50*	-1.60	-2.79^{*}
	488.1 (398.4–556.2)	506.2(424.3 - 589.0)	+4.0	543.5(483.3 - 598.5)	+7.4	00.01	(-0.30)	(-0.53)
	21.1 ± 5.6	25.9 ± 3.7		24.9 ± 4.3	C 01 -	17 00*	-3.20^{*}	-2.59^{*}
FUA (SCOFE)	21.0 (16.5–26.0)	27.0 (22.8–29.0)	C:77+	25.5 (22.0-29.0)	+10.2	11.00	(-0.60)	(-0.49)
(man) [other	68.1 ± 13.9	76.0 ± 11.1	217	74.7 ± 15.0	201		-2.23	-2.35
MusiQoi (score)	69.2 (58.7-82.6)	77.5 (64.9-84.4)	41.0	73.9 (59.5–90.3)	+9.0	7./1	(-0.42)	(-0.44)
TATETAA	22.9 ± 14.7	18.6 ± 12.8	- 10 7	20.6 ± 14.9	- 10 2	1 52	-1.26	-0.74
VY ELIVIUS (SCULE)	26.5 (12.5–32.8)	17.0 (9.5–27.3)	1.017	18.5 (8.8–32.3)	C.017	CC.1	(-0.24)	(-0.14)
manual fati man (and)	9.2 ± 7.8	8.5 ± 6.9	0	9.5 ± 9.0	1 0	110	-0.77	-0.45
membre (score)	7.0 (4.8–12.3)	7.5 (2.8–13.5)	0.17	(1.5 - 14.0)	1.0-	0.41	(-0.14)	(-0.08)
hireiral fatimia (ecora)	13.7 ± 9.2	10.1 ± 7.0	176.0	11.1 ± 7.8	+10.3	2 00	-1.56	-1.91
purparcar rangue (acure)	17.5(4.8-22.0)	10.0(4.8 - 13.3)	120.02	9.5(4.5-20.0)	CCTL	00.7	(-0.29)	(-0.36)
CCA (Contra)	4.7 ± 1.2	4.5 ± 1.2	V V	4.9 ± 1.1	0.14	200	-0.31	-0.97
(and (acoust)	4.9(3.4-5.6)	4.5(3.6-4.9)	-4.4	4.9(3.7-5.2)	T4.U	07.7	(-0.06)	(-0.18)
<u>Note</u> . Positive percentage values indicate improvements and negative per Rank test. Effect size r was computed using formula $r = z/s$ quare root Rank test (two-tailed) with Bonferroni adjustment for three measurem $T2/T2^{1}$, measurements of the T2 words calf completed training period. CD	ulues indicate improven computed using form Bonferroni adjustment	nents and negative percent ula $r = z/square root of N$ t for three measurements; t trining neuron 4. CD. storus;	age values indica V; * denotes stat EG-all: all partic	te declines; X^2 -scores we istical significance ($p \leq$ ipants receiving ePEP (E OD: internomination conce (C	re taken from result. 0.05) for exact p va G-1 + EG-W); $T0/T$	s of Friedman test; Z-s. lues of Friedman test (0': baseline measurem	Note. Positive percentage values indicate improvements and negative percentage values indicate declines; X^2 -scores were taken from results of Friedman test; Z-scores were taken from results of Wilcoxon Signed Rank test. Effect size <i>r</i> was computed using formula $r = z/square$ root of N; * denotes statistical significance ($p \le 0.05$) for exact <i>p</i> values of Friedman test (two-tailed) or exact <i>p</i> value of Wilcoxon Signed Rank test. Effect size <i>r</i> was computed using formula $r = z/square$ root of N; * denotes statistical significance ($p \le 0.05$) for exact <i>p</i> values of Friedman test (two-tailed) or exact <i>p</i> value of Wilcoxon Signed Rank test. Effect size <i>r</i> was computed using formula <i>r</i> here measurements; EG-all: all participants receiving ePEP (EG-1 + EG-W); T0/T0'; baseline measurements; T1/T1': measurements after six-week ePEP T2/T2': measurements; T2/T2': measurements; EG-all: all participants receiving ePEP (EG-1 + EG-W); T1/T2': Dirach T1, Dask for MMTT. Six Minute Molt Task FGA & Dave FGA &	s of Wilcoxon Signed e of Wilcoxon Signed after six-week ePEP;
Gait Assessment; MusiQol: Multi efficacy towards physical exercise.	Multiple Sclerosis Inter ercise.	rnational Questionnaire of	Quality of Life;	WEIMuS: German MS-s	secific fatigue questi	onnaire—lower values	Gait Assessment; MusiQol: Multiple Sclerosis International Questionnaire of Quality of Life; WEIMuS: German MS-specific fatigue questionnaire—lower values indicate fatigue improvement; SSA: scale for self- efficacy towards physical exercise.	it; SSA: scale for self-

uasi-experimental design outcomes in walking ability, QoL, fatigue, and self-efficacy for EG-all in baseline (T0/T0 ¹), after the six-week ePEP (T1/T1 ¹) and after the 12-week	ed training period $(T2/T2')$.	
TABLE 4: Quasi-experimenta	self-regulated training period	

TABLE 5: Quasi-experimental design outcomes in walking ability, QoL, fatigue, and self-efficacy for EG-all in baseline (T0/T0') and one year after baseline (T3).

		EG-a	ll $(n = 8)$		
Variable	T0/T0' mean ± SD median (IQR)	T3mean ± SD median (IQR)	Percentage change T0-T1	Z-score	Effect size r
TUG (s)	7.6 ± 1.4 7.7 (6.3–8.7)	6.8 ± 1.5 6.7 (5.6–7.3)	+11.1	-2.38*	-0.60
6MWT (m)	494.8 ± 129.2 461.2 (390.8–569.8)	513.8 ± 115.9 500.2 (468.4–580.8)	+3.8	-0.84	-0.21
FGA (score)	22.0 ± 6.7 23.0 (15.7–27.5)	23.8 ± 4.3 24.5 (23.0–26.8)	+8.0	-0.84	-0.21
MusiQol (score)	64.4 ± 15.4 67.7 (51.9–79.4)	69.0 ± 14.2 67.9 (56.2–82.9)	+7.1	-1.88	-0.42
WEIMuS (score)	19.8 ± 10.5 21.5 (14.0–27.8)	14.6 ± 7.0 14.5 (9.0–20.8)	+26.0	-1.36	-0.34
Mental fatigue (score)	6.6 ± 3.2 7.0 (5.25–9.0)	4.9 ± 3.0 4.0 (0.8–7.0)	+35.9	-1.36	-0.34
Physical fatigue (score)	13.1 ± 9.1 13.5 (5.5–22.0)	10.4 ± 6.6 7.5 (5.0–18.0)	+20.6	-1.05	-0.26
SSA (score)	4.9 ± 1.4 5.1 (5.3–9.0)	4.3 ± 0.8 4.6 (3.7–5.0)	-6.7	-1.18	-0.30

Note. Positive percentage values indicate improvements and negative percentage values indicate declines; *Z*-scores were taken from results of Wilcoxon Signed Rank test. Effect size *r* was computed using formula r = z/square root of *N*; * denotes statistical significance ($p \le 0.05$) for exact *p* value of Wilcoxon Signed Rank test (two-tailed); EG-all: all participants receiving ePEP (EG-I + EG-W); T0/T0': baseline measurements; *T*3: measurements one year after baseline; SD: standard deviation; IQR: interquartile range (25th–75th); TUG: Timed-Up-and-Go-Test; 6MWT: Six-Minute-Walk-Test; FGA: Functional Gait Assessment; MusiQol: Multiple Sclerosis International Questionnaire of Quality of Life; WEIMuS: German MS-specific fatigue questionnaire—lower values indicate fatigue improvement; SSA: scale for self-efficacy towards physical exercise.

FGA (Z = -3.20, p = 0.001, and r = -0.60) and for TUG (Z = -2.45, p = 0.033, and r = -0.46) as well as significant improvements from T0/T0' to T2/T2' for TUG (Z = -2.76, p = 0.010, and r = -0.52), 6MWT (Z = -2.79, p = 0.009, and r = -0.53), and FGA (Z = -2.59, p = 0.018, and r = -0.49). There were no significant differences for MusiQol, WEIMuS (total, mental, and physical fatigue), and SSA. However, small to moderate effect sizes were detected for MusiQol (T1/T1': Z = -2.23, r = -0.42; T2/T2': Z = -2.35, r = -0.44), total fatigue (T1/T1': Z = -1.26, r = -0.24; T2/T2': Z = -0.74, r = -0.14), and physical fatigue (T1/T1': Z = -1.56, r = -0.29; T2/T2': Z = -1.91, r = -0.36) in both times. Mental fatigue and SSA showed no or only small effect sizes. Please see Table 4.

3.4. Long-Term Effects of Intervention 30 or 36 Weeks after ePEP (QED). Due to the loss of six participants in the followup test one year after baseline, data from the remaining eight participants were compared to baseline data. This analysis showed significant long-term effects with large effect sizes for TUG (Z = -2.38, p = 0.016, and r = -0.60) only. Small to moderate effect sizes with superior mean values were detected for 6MWT (Z = -0.84, r = -0.21), FGA (Z = -0.84, r = -0.21), MusiQol (Z = -1.88, r = 0.42), total fatigue (Z = -1.36, r = -0.34), mental fatigue (Z = -1.36, r = -0.34), and physical fatigue (Z = -1.18, r = -0.26). SSA decreased with a moderate effect (Z = -1.18, r = -0.3). Please see Table 5.

4. Discussion

This exercise-based patient education programme was developed to integrate a goal-oriented, effective, and self-regulated exercise training management in the daily life of pwMS. Drawing from a complex adaptive systems theory [59], the present comprehensive approach focused on considering individual and disease-related needs and goals (e.g., abilities and disabilities, everyday challenges, and character profiles) in a face-to-face intervention. A successful implementation of exercise training in patients' daily life should be reflected in improved walking ability, QoL, fatigue, and *self-efficacy* towards physical exercise. The results of the RCT analysis demonstrated significant improvements with large effects in functional gait for the six-week ePEP group compared to the waitlist-control group. Analysis of all ePEP participants in the QED confirmed this improvement for FGA and, in addition, it identified significant improvements with moderate to large effects in walking endurance and in walking speed immediately and 12 weeks after the ePEP. The benefits in walking speed could be maintained one year after the baseline measurements. The positive study results by Kersten et al. [23] for walking ability, due to teaching pwMS essentials of the MS disease, exercises, and training management, have been confirmed in this revised form of ePEP.

Moreover, the benefits of our study are consistent with the results of three meta-analyses concerning the impact of exercise training on walking mobility [60], QoL [61], and fatigue [62]. These meta-analyses reported an overall small effect from exercise training on walking mobility (Hedges' g = 0.19) [60] and QoL (Hedges' g = 0.23) [61] as well as an overall moderate effect on fatigue (Cohen's d = 0.45) [62]. Most of these included studies only analysed short-term effects of exercise training. This study at hand showed similar short-term effects linked with small to large effect sizes for walking ability and QoL and, additionally, moderate to large long-term effects for walking ability, QoL, and fatigue.

Regarding RCT analysis, only functional gait (FGA) improved immediately after the ePEP in EG-I compared to EG-W. The high amount of DGT with its specific training stimulus trained the participants' functional ability to adopt and perform several different walking tasks such as in the FGA. In contrast, walking speed (TUG) and walking endurance (6MWT) did not change significantly in RCT analysis. We assume that the participants' knowledge of being part of an intervention probably caused effects on unspecific walking and psychometric outcomes in the waitlist-control group (John-Henry-Effect) [63]. This is also confirmed by unpublished qualitative data of the study. Participants of the waitlist-control group reported in semi-structured interviews that they were motivated to be more active in their daily lives after the baseline test although they were instructed not to change their daily routines. The beneficial change in FGA and TUG in QED analysis is attributable to neuronal and functional adaptations, whereas the steady-state of walking endurance from T0/T0' to T1/T1' and the delayed significant increase from T0/T0' to T2/T2' is probably caused by delayed aerobic and morphologic adaptations. Information from qualitative data indicated that during the 12-week selfregulated training period most of the participants focused their exercise training more on endurance than on walking speed or functional gait. The participants reported that they had implemented exercise training in their daily lives; however, they performed exercises less than intended by their self-generated training schedule.

Only a few studies have examined long-term effects of exercise training. For example, Schwartz et al. [64] evaluated both short- and long-term effects of a robotassisted gait training (RAGT) compared to conventional gait training (CGT) in gait parameters. Both groups significantly improved after the four-week intervention; however, only the CGT group showed long-term effects with still higher scores compared to baseline. RAGT, CGT, and the ePEP focused on gait exercises, which lead to short-term effects due to the specific stimulus for gait performance. In contrast, long-term effects on walking ability are caused by the functional gait exercises in the CGT and ePEP and also by the transfer of competences in exercise training and training management in the ePEP. Considering that walking difficulties are the most challenging aspects of having MS [65], improvements or maintenance in walking ability allows patients to participate in daily life, which is a very meaningful aspect of the patients' QoL.

Relevant nonsignificant short-term and long-term improvements with moderate effect sizes were detected for QoL and fatigue. Comparing the baseline MusiQol score (mean \pm SD 68.1 \pm 13.9) with the MusiQol score from an international control sample of 1,992 pwMS (mean \pm SD 65.82 \pm 14.75) [52], the ePEP sample showed already higher baseline scores with further improvements after the PEP. Although these improvements failed statistical significance, the index score increased about 7.9 points with a moderate effect. This reveals a relevant benefit regarding that pwMS with a mild clinical global impression of severity (CGI) differ in the MusiQol score about 10 points from pwMS with a severe CGI [52].

No significant differences were detected for fatigue scores between EG-I and EG-W after the six-week ePEP. Although total fatigue improved in both groups, Table 4 shows that the EG-I mainly improved in physical fatigue whereas the EG-W improved in mental fatigue. This might be an indication of a positive reaction to the physical stimulus in the ePEP [66]. Analyses of EG-all indicated a decrease in fatigue symptoms immediately after the ePEP with a small effect, a slight increase after the 12-week self-regulated training period, and a further decrease with a moderate effect one year after baseline. In this study, we did not differentiate between fatigue and nonfatigue participants in the analyses. The inclusion of both fatigue and nonfatigue participants in analyses might have impeded significant results and is also known as a predicted reason for heterogeneous findings of exercise training on fatigue in literature [67].

Self-efficacy towards physical exercise improved neither in RCT nor in quasi-experimental analyses, although methods based on psychological theories for enhancing self-efficacy [40] were applied in the programme. These results are similar to the results of the Internet intervention for increasing physical activity by Motl et al. [19], which were based on SCT for increasing self-efficacy. Noticeably, baseline scores of SSA in both groups (mean \pm SD EG-I: 4.7 ± 0.7 ; EG-W: 4.4 ± 1.3) and EG-all (mean \pm SD 4.7 ± 1.2) are higher compared to scores of norm population of the same age (mean \pm SD 3.52 \pm 1.5) [56]. Based on findings from unpublished qualitative data (semi-structured interviews), a possible reason for the high SSA score in this study might be the participation of primarily patients with a high affinity to sporting activities. This raises the question, if there is even a further increase possible.

Due to the small sample size, the terminated control group, and a possible clustering, the results of this pilot study allow a limited interpretation. However, the face-to-face education concept of ePEP required a small sample size to guarantee individual guiding and counselling. A multicentre study with a larger sample size is needed to confirm the results. A larger sample size would also allow a more balanced distribution of the gender and a multivariate analysis of confounding effects such as gender, EDSS score, and type of MS. A limitation of this study is that there was no balancing of gender in the sample size and no multivariate analysis to consider confounding effects. The voluntary participation at the ePEP, the fixed starting point of the study, and the higher prevalence of MS in women than in men (ratio 2.3-3.5:1) [68] might be reasons for the nonbalanced distribution of gender in the sample size. Furthermore, the results of the QED analysis only allow a limited interpretation due to the fact that a control group is missing and that data from two exercise groups (EG-I + EG-W after their control period) were merged. This was necessary to detect effects of the ePEP in a more meaningful sample size, immediately after the ePEP, after the 12-week self-regulated training period, and one year after baseline. Resulting from data merging of the two groups, there is a time-shift of six weeks within the participants at the one-year follow-up test (EG-W = 30 weeks and EG-I = 36 weeks). Nevertheless, we set a fixed date for the start and end of the study with the assumption that six weeks-more or less—over the span of one year will not influence the results in a significant amount. The negligence of possible occurring relapses and changes in medical treatment during the 30- and 36-week self-regulated training period might have influenced the outcomes at the one-year follow-up test. We are aware of these influences; however, we did not want to intervene in patients' medical treatment decisions and we did not want to exclude participants from analysis that had relapses. The occurrence of relapses is part of the nature of the disease and should not be excluded in the analysis of long-term effects. Furthermore, there are multiple factors in patients' daily life and disease management that we cannot control in a longterm "field study" and that probably have an impact on the outcomes. That is probably the main reason for the lack of long-term studies in MS (and exercise training). Reducing the impact on the outcomes, occurrences of MS relapse, changing medication, or cortisone therapy one month prior to the follow-up test were applied as exclusion criteria. Last but not least, the participants' knowledge of being part of an intervention probably caused effects on outcomes in waitlistcontrol group (John-Henry-Effect) [63]. An extended control period besides the 12-week self-regulated training period might minimise this effect.

5. Conclusion

Although the RCT analysis of the six-week ePEP only showed improvements in functional gait, the results of QED detected significant short- and long-term benefits in walking ability as well as relevant benefits in QoL and fatigue. This suggests a realisation of a sustainable and independent training management by pwMS beyond the programme that have resulted in important benefits in walking ability. This ePEP is a feasible and comprehensive approach with the choice of various effective and evidence-based exercises and sport possibilities according to individual needs and preferences concerning MS-specific challenges in training management. The participants also gained knowledge and skills to train independently, economically, flexibly, and goaloriented without any appointments, journeys, or any special equipment. Regarding that MS is a chronic and degenerative disease with a progression of disabilities, an improvement or nonworsening health condition is a benefit for the patient and its daily life participation. Nevertheless, a further RCT with an optimal sample size should be conducted to confirm the short- and long-term benefits of this ePEP. Providing the contents of ePEP as a weekend workshop could be another possibility of reaching those pwMS who are employed, have families, or live in rural areas.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments

The authors would like to thank the Aenne Speck Foundation and IKK Südwest for their financial support. They also thank the German MS Society (Department Saarland and Rheinland-Pfalz) and Professor Georg Wydra (Sport Science Institute, Saarland University) for the organisational support.

References

- M. Asano, D. J. Dawes, A. Arafah, C. Moriello, and N. E. Mayo, "What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials?" *Multiple Sclerosis*, vol. 15, no. 4, pp. 412–421, 2009.
- [2] R. W. Motl and L. A. Pilutti, "The benefits of exercise training in multiple sclerosis," *Nature Reviews Neurology*, vol. 8, no. 9, pp. 487–497, 2012.
- [3] R. W. Motl and B. M. Sandroff, "Benefits of Exercise Training in Multiple Sclerosis," *Current Neurology and Neuroscience Reports*, vol. 15, no. 9, p. 62, 2015.
- [4] A. E. Latimer-Cheung, L. A. Pilutti, A. L. Hicks et al., "Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development," *Archives of Physical Medicine and Rehabilitation*, vol. 94, no. 9, pp. 1800–1828.e3, 2013.
- [5] M. B. Rietberg, D. Brooks, B. M. J. Uitdehaag, and G. Kwakkel, "Exercise therapy for multiple sclerosis," *The Cochrane Database* of Systematic Reviews, no. 1, Article ID CD003980, 2005.
- [6] L. J. White and R. H. Dressendorfer, "Exercise and multiple sclerosis," *Sports Medicine*, vol. 34, no. 15, pp. 1077–1100, 2004.
- [7] R. W. Motl, E. McAuley, and E. M. Snook, "Physical activity and multiple sclerosis: a meta-analysis," *Multiple Sclerosis*, vol. 11, no. 4, pp. 459–463, 2005.
- [8] S. Kersten, M. Mahli, and C. Haas, "Zum Sport- und Bewegungsverhalten von Multiple Sklerose-Patienten – eine explorative Analyse," *Aktuelle Neurologie*, vol. 41, no. 02, pp. 100–106, 2014.
- [9] M. W. Nortvedt, T. Riise, and J. G. Mæland, "Multiple sclerosis and lifestyle factors: The Hordaland Health Study," *Neurological Sciences*, vol. 26, no. 5, pp. 334–339, 2005.
- [10] A. Compston and A. Coles, "Multiple sclerosis," *The Lancet*, vol. 359, no. 9313, pp. 1221–1231, 2002.
- [11] M. E. Morris, C. Cantwell, L. Vowels, and K. Dodd, "Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis," *Journal of Neurology Neurosurgery and Psychiatry*, vol. 72, no. 3, pp. 361–365, 2002.
- [12] H. Beckerman, V. De Groot, M. A. Scholten, J. C. E. Kempen, and G. J. Lankhorst, "Physical activity behavior of people with multiple sclerosis: Understanding how they can become more physically active," *Physical Therapy*, vol. 90, no. 7, pp. 1001–1013, 2010.
- [13] C. Heesen, J. Bruce, R. Gearing et al., "Adherence to behavioural interventions in multiple sclerosis: Follow-up meeting report

(AD@MS-2)," Multiple Sclerosis Journal – Experimental, Translational and Clinical, vol. 1, pp. 1–4, 2015.

- [14] F. Petermann, Patientenschulung und Patientenberatung: Ein Lehrbuch, Hogrefe, Göttingen, Germany, 2nd edition, 1997.
- [15] S. R. Weingarten, J. M. Henning, E. Badamgarav et al., "Interventions used in disease management programmes for patients with chronic illnesswhich ones work? Meta-analysis of published reports," *BMJ*, vol. 325, no. 7370, p. 925, 2002.
- [16] S. Demaille-Wlodyka, C. Donze, P. Givron, and P. Gallien, "Self care programs and multiple sclerosis: physical therapeutics treatment—literature review," *Annals of Physical and Rehabilitation Medicine*, vol. 54, no. 2, pp. 109–128, 2011.
- [17] S. Kersten, C. Lutz, J. Drosselmeyer, M. Liebherr, and P. Schubert, "Sport- und bewegungsorientierte Patientenschulungen für Personen mit Multipler Sklerose," *Aktuelle Neurologie*, vol. 42, no. 9, pp. 522–534, 2015.
- [18] A. Tallner, R. Streber, C. Hentschke et al., "Internet-supported physical exercise training for persons with multiple sclerosis—a randomised, controlled study," *International Journal of Molecular Sciences*, vol. 17, no. 10, article no. 1667, 2016.
- [19] R. W. Motl, D. Dlugonski, T. R. Wójcicki, E. McAuley, and D. C. Mohr, "Internet intervention for increasing physical activity in persons with multiple sclerosis," *Multiple Sclerosis*, vol. 17, no. 1, pp. 116–128, 2011.
- [20] D. Dlugonski, R. W. Motl, and E. Mcauley, "Increasing physical activity in multiple sclerosis: replicating internet intervention effects using objective and self-report outcomes," *Journal of Rehabilitation Research and Development*, vol. 48, no. 9, pp. 1129–1136, 2011.
- [21] D. Dlugonski, R. W. Motl, D. C. Mohr, and B. M. Sandroff, "Internet-delivered behavioral intervention to increase physical activity in persons with multiple sclerosis: sustainability and secondary outcomes," *Psychology, Health & Medicine*, vol. 17, no. 6, pp. 636–651, 2012.
- [22] A. M. Carter, A. J. Daley, S. W. Kesterton, N. M. Woodroofe, J. M. Saxton, and B. Sharrack, "Pragmatic exercise intervention in people with mild to moderate multiple sclerosis: A randomised controlled feasibility study," *Contemporary Clinical Trials*, vol. 35, no. 2, pp. 40–47, 2013.
- [23] S. Kersten, M. Mahli, J. Drosselmeyer et al., "A Pilot Study of an Exercise-Based Patient Education Program in People with Multiple Sclerosis," *Multiple Sclerosis International*, vol. 2014, pp. 1–11, 2014.
- [24] U. Dalgas, E. Stenager, and T. Ingemann-Hansen, "Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training," *Multiple Sclerosis*, vol. 14, no. 1, pp. 35–53, 2008.
- [25] C. T. Haas, S. Kersten, M. Lutz, and C. Schwed, "Deviance - based gait training in multiple sclerosis," *Isokinetics and Exercise*, vol. 18, pp. 82-83, 2010.
- [26] S. M. Gold, K.-H. Schulz, S. Hartmann et al., "Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls," *Journal of Neuroimmunology*, vol. 138, no. 1-2, pp. 99–105, 2003.
- [27] J. Collett, H. Dawes, A. Meaney et al., "Exercise for multiple sclerosis: A single-blind randomized trial comparing three exercise intensities," *Multiple Sclerosis Journal*, vol. 17, no. 5, pp. 594–603, 2011.

- [28] C. Le Page, A. Ferry, and M. Rieu, "Effect of muscular exercise on chronic relapsing experimental autoimmune encephalomyelitis," *Journal of Applied Physiology*, vol. 77, no. 5, pp. 2341– 2347, 1994.
- [29] I. Wens, U. Dalgas, K. Verboven et al., "Impact of high intensity exercise on muscle morphology in eae rats," *Physiological Research*, vol. 64, no. 6, pp. 907–923, 2015.
- [30] V. Castellano and L. J. White, "Serum brain-derived neurotrophic factor response to aerobic exercise in multiple sclerosis," *Journal of the Neurological Sciences*, vol. 269, no. 1-2, pp. 85–91, 2008.
- [31] K. J. Hutchinson, F. Gómez-Pinilla, M. J. Crowe, Z. Ying, and D. M. Basso, "Three exercise paradigms differentially improve sensory recovery after spinal cord contusion in rats," *Brain*, vol. 127, part 6, pp. 1403–1414, 2004.
- [32] S. Vaynman and F. Gomez-Pinilla, "License to run: exercise impacts functional plasticity in the intact and injured central nervous system by using neurotrophins," *Neurorehabilitation and Neural Repair*, vol. 19, no. 4, pp. 283–295, 2005.
- [33] M. Caggiula, A. P. Batocchi, G. Frisullo et al., "Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis," *Scandinavian Journal of Immunology*, vol. 62, no. 2, pp. 176–182, 2005.
- [34] J. L. Tillerson, A. D. Cohen, W. M. Caudle, M. J. Zigmond, T. Schallert, and G. W. Miller, "Forced nonuse in unilateral Parkinsonian rats exacerbates injury," *Journal of Neuroscience*, vol. 22, no. 15, pp. 6790–6799, 2002.
- [35] P. Sarchielli, L. Greco, A. Stipa, A. Floridi, and V. Gallai, "Brainderived neurotrophic factor in patients with multiple sclerosis," *Journal of Neuroimmunology*, vol. 132, no. 1-2, pp. 180–188, 2002.
- [36] D. Azoulay, V. Vachapova, B. Shihman, A. Miler, and A. Karni, "Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate," *Journal of Neuroimmunology*, vol. 167, no. 1-2, pp. 215–218, 2005.
- [37] D. Azoulay, N. Urshansky, and A. Karni, "Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection," *Journal of Neuroimmunology*, vol. 195, no. 1-2, pp. 186–193, 2008.
- [38] R. A. Schmidt and T. D. Lee, *Motor Learning and Performance: From Principles to Application*, Human Kinetics, Champaign, Ill, USA, 5th edition, 2014.
- [39] T. Bodenheimer, K. Lorig, H. Holman, and K. Grumbach, "Patient self-management of chronic disease in primary care," *Journal of the American Medical Association*, vol. 288, no. 19, pp. 2469–2475, 2002.
- [40] A. Bandura, Self-Efficacy the Exercise of Control, Freeman, New York, USA, 1997.
- [41] H. A. Schut and H. J. Stam, "Goals in rehabilitation team work," *Disability and Rehabilitation*, vol. 16, no. 4, pp. 223–226, 1994.
- [42] R. O. Crapo, R. Casaburi, A. L. Coates et al., "ATS statement: guidelines for the six-minute walk test," *American Journal of Respiratory and Critical Care Medicine*, vol. 166, no. 1, pp. 111– 117, 2002.
- [43] M. D. Goldman, R. A. Marrie, and J. A. Cohen, "Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls," *Multiple Sclerosis*, vol. 14, no. 3, pp. 383–390, 2008.
- [44] S. Savci, D. Inal-Ince, H. Arikan et al., "Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis," *Disability and Rehabilitation*, vol. 27, no. 22, pp. 1365– 1371, 2005.

- [45] D. Podsiadlo and S. Richardson, "The timed "Up and Go": a test of basic functional mobility for frail elderly persons," *Journal of the American Geriatrics Society*, vol. 39, no. 2, pp. 142–148, 1991.
- [46] Y. Nilsagard, C. Lundholm, L.-G. Gunnarsson, and E. Dcnison, "Clinical relevance using timed walk tests and 'timed up and go' testing in persons with multiple sclerosis," *Physiotherapy Research International*, vol. 12, no. 2, pp. 105–114, 2007.
- [47] D. M. Wrisley, G. F. Marchetti, D. K. Kuharsky, and S. L. Whitney, "Reliability, internal consistency, and validity of data obtained with the functional gait assessment," *Physical Therapy*, vol. 84, no. 10, pp. 906–918, 2004.
- [48] D. M. Wrisley and N. A. Kumar, "Functional gait assessment: concurrent, discriminative, and predictive validity in community-dwelling older adults," *Physical Therapy*, vol. 90, no. 5, pp. 761–773, 2010.
- [49] J.-H. Lin, M.-J. Hsu, H.-W. Hsu, H.-C. Wu, and C.-L. Hsieh, "Psychometric comparisons of 3 functional ambulation measures for patients with stroke," *Stroke*, vol. 41, no. 9, pp. 2021– 2025, 2010.
- [50] T. Ellis, J. T. Cavanaugh, G. M. Earhart, M. P. Ford, K. B. Foreman, and L. E. Dibble, "Which measures of physical function and motor impairment best predict quality of life in Parkinson's disease?" *Parkinsonism & Related Disorders*, vol. 17, no. 9, pp. 693–697, 2011.
- [51] M. L. Walker, A. G. Austin, G. M. Banke et al., "Reference group data for the functional gait assessment," *Physical Therapy*, vol. 87, no. 11, pp. 1468–1477, 2007.
- [52] M. Simeoni, P. Auquier, O. Fernandez et al., "Validation of the Multiple Sclerosis International Quality of Life questionnaire," *Multiple Sclerosis*, vol. 14, 219, no. 2, p. 230, 2008.
- [53] P. Flachenecker, U. Vogel, M. C. Simeoni, P. Auquier, and P. Rieckmann, "MusiQol: International questionnaire investigating quality of life in multiple sclerosis: Ults for the German subpopulation in an international comparison," *Nervenarzt*, vol. 82, no. 10, pp. 1281–1289, 2011.
- [54] O. Fernández, K. Baumstarck-Barrau, M.-C. Simeoni, and P. Auquier, "Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: Assessment using the MusiQoL and SF-36 questionnaires," *Multiple Sclerosis Journal*, vol. 17, no. 10, pp. 1238–1249, 2011.
- [55] P. Flachenecker, H. König, H. Meissner, G. Müller, and P. Rieckmann, "Fatigue in multiple sclerosis: Validation of the WEIMuS scale ("Würzburger Erschöpfungs-Inventar bei Multipler Sklerose")," *Neurologie und Rehabilitation*, vol. 14, no. 6, pp. 299–306, 2008.
- [56] R. Fuchs and R. Schwarzer, "Self-efficacy toward physical exercise: Reliability and validity of a new instrument," *Zeitschrift für Differentielle und Diagnostische Psychologie*, vol. 15, pp. 141– 154, 1994.
- [57] R. Rosenthal, Meta-Analytic Procedures for Social Research, Sage, Newbury Park, Calif, USA, 2nd edition, 1991.
- [58] J. Cohen, Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum Associates, New York, USA, 2nd edition, 1988.
- [59] C. A. Brown, "The application of complex adaptive systems theory to clinical practice in rehabilitation," *Disability and Rehabilitation*, vol. 28, no. 9, pp. 587–593, 2006.
- [60] E. M. Snook and R. W. Motl, "Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis," *Neurorehabilitation and Neural Repair*, vol. 23, no. 2, pp. 108–116, 2009.

- [61] R. W. Motl and J. L. Gosney, "Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis," *Multiple Sclerosis*, vol. 14, no. 1, pp. 129–135, 2008.
- [62] L. A. Pilutti, T. A. Greenlee, R. W. Motl, M. S. Nickrent, and S. J. Petruzzello, "Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis," *Psychosomatic Medicine*, vol. 75, no. 6, pp. 575–580, 2013.
- [63] M. Pospeschill, Empirische Methoden in der Psychologie, Reinhardt, Munich, Germany, 2013.
- [64] I. Schwartz, A. Sajin, E. Moreh et al., "Robot-assisted gait training in multiple sclerosis patients: A randomized trial," *Multiple Sclerosis Journal*, vol. 18, no. 6, pp. 881–890, 2012.
- [65] N. G. LaRocca, "Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners," *The Patient: Patient-Centered Outcomes Research*, vol. 4, no. 3, pp. 189–201, 2011.
- [66] M. Langeskov-Christensen, E. J. Bisson, M. L. Finlayson, and U. Dalgas, "Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review," *Journal of the Neurological Sciences*, vol. 373, pp. 307–320, 2017.
- [67] A. K. Andreasen, E. Stenager, and U. Dalgas, "The effect of exercise therapy on fatigue in multiple sclerosis," *Multiple Sclerosis*, vol. 17, no. 9, pp. 1041–1054, 2011.
- [68] H. F. Harbo, R. Gold, and M. Tintoré, "Sex and gender issues in multiple sclerosis," *Therapeutic Advances in Neurological Disorders*, vol. 6, no. 4, pp. 237–248, 2013.